277 related articles for article (PubMed ID: 9539768)
1. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance.
Paul P; Rouas-Freiss N; Khalil-Daher I; Moreau P; Riteau B; Le Gal FA; Avril MF; Dausset J; Guillet JG; Carosella ED
Proc Natl Acad Sci U S A; 1998 Apr; 95(8):4510-5. PubMed ID: 9539768
[TBL] [Abstract][Full Text] [Related]
2. HLA-G expression in human melanoma cells: protection from NK cytolysis.
Adrián Cabestré F; Moreau P; Riteau B; Ibrahim EC; Le Danff C; Dausset J; Rouas-Freiss N; Carosella ED; Paul P
J Reprod Immunol; 1999 Jul; 43(2):183-93. PubMed ID: 10479054
[TBL] [Abstract][Full Text] [Related]
3. The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors?
Rouas-Freiss N; Marchal RE; Kirszenbaum M; Dausset J; Carosella ED
Proc Natl Acad Sci U S A; 1997 May; 94(10):5249-54. PubMed ID: 9144223
[TBL] [Abstract][Full Text] [Related]
4. HLA-G in skin cancer: a wolf in sheep's clothing?
Urosevic M; Dummer R
Hum Immunol; 2003 Nov; 64(11):1073-80. PubMed ID: 14602238
[TBL] [Abstract][Full Text] [Related]
5. Switch of HLA-G alternative splicing in a melanoma cell line causes loss of HLA-G1 expression and sensitivity to NK lysis.
Rouas-Freiss N; Bruel S; Menier C; Marcou C; Moreau P; Carosella ED
Int J Cancer; 2005 Oct; 117(1):114-22. PubMed ID: 15880415
[TBL] [Abstract][Full Text] [Related]
6. HLA-G in melanoma: A new strategy to escape from immunosurveillance?
Ugurel S; Reinhold U; Tilgen W
Onkologie; 2002 Apr; 25(2):129-34. PubMed ID: 12006763
[TBL] [Abstract][Full Text] [Related]
7. Human melanoma cell secreting human leukocyte antigen-G5 inhibit natural killer cell cytotoxicity by impairing lytic granules polarization toward target cell.
Lesport E; Baudhuin J; LeMaoult J; Sousa S; Doliger C; Carosella ED; Favier B
Hum Immunol; 2009 Dec; 70(12):1000-5. PubMed ID: 19654030
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies.
Paul P; Cabestré FA; Le Gal FA; Khalil-Daher I; Le Danff C; Schmid M; Mercier S; Avril MF; Dausset J; Guillet JG; Carosella ED
Cancer Res; 1999 Apr; 59(8):1954-60. PubMed ID: 10213506
[TBL] [Abstract][Full Text] [Related]
9. MICA triggering signal for NK cell tumor lysis is counteracted by HLA-G1-mediated inhibitory signal.
Menier C; Riteau B; Carosella ED; Rouas-Freiss N
Int J Cancer; 2002 Jul; 100(1):63-70. PubMed ID: 12115588
[TBL] [Abstract][Full Text] [Related]
10. [HLA-G: a tolerance molecule implicated in the escape of tumors from immunosurveillance].
Paul P; Rouas-Freiss N; Carosella ED
Pathol Biol (Paris); 1999 Oct; 47(8):766-70. PubMed ID: 10573693
[TBL] [Abstract][Full Text] [Related]
11. Exosomes bearing HLA-G are released by melanoma cells.
Riteau B; Faure F; Menier C; Viel S; Carosella ED; Amigorena S; Rouas-Freiss N
Hum Immunol; 2003 Nov; 64(11):1064-72. PubMed ID: 14602237
[TBL] [Abstract][Full Text] [Related]
12. Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene.
Maio M; Altomonte M; Tatake R; Zeff RA; Ferrone S
J Clin Invest; 1991 Jul; 88(1):282-9. PubMed ID: 1905328
[TBL] [Abstract][Full Text] [Related]
13. Analysis of HLA-E expression in human tumors.
Marín R; Ruiz-Cabello F; Pedrinaci S; Méndez R; Jiménez P; Geraghty DE; Garrido F
Immunogenetics; 2003 Feb; 54(11):767-75. PubMed ID: 12618909
[TBL] [Abstract][Full Text] [Related]
14. Differential in vivo and in vitro HLA-G expression in melanoma cells: potential mechanisms.
Chang CC; Murphy SP; Ferrone S
Hum Immunol; 2003 Nov; 64(11):1057-63. PubMed ID: 14602236
[TBL] [Abstract][Full Text] [Related]
15. HLA-G promotes immune tolerance.
Rouas-Freiss N; Paul P; Dausset J; Carosella ED
J Biol Regul Homeost Agents; 2000; 14(2):93-8. PubMed ID: 10841284
[TBL] [Abstract][Full Text] [Related]
16. HLA-G expression in malignant melanoma.
Rebmann V; Wagner S; Grosse-Wilde H
Semin Cancer Biol; 2007 Dec; 17(6):422-9. PubMed ID: 17689098
[TBL] [Abstract][Full Text] [Related]
17. Increase in HLA-G1 proteolytic shedding by tumor cells: a regulatory pathway controlled by NF-kappaB inducers.
Zidi I; Guillard C; Marcou C; Krawice-Radanne I; Sangrouber D; Rouas-Freiss N; Carosella ED; Moreau P
Cell Mol Life Sci; 2006 Nov; 63(22):2669-81. PubMed ID: 17072500
[TBL] [Abstract][Full Text] [Related]
18. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis.
Rouas-Freiss N; Gonçalves RM; Menier C; Dausset J; Carosella ED
Proc Natl Acad Sci U S A; 1997 Oct; 94(21):11520-5. PubMed ID: 9326642
[TBL] [Abstract][Full Text] [Related]
19. Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy.
Ugurel S; Rebmann V; Ferrone S; Tilgen W; Grosse-Wilde H; Reinhold U
Cancer; 2001 Jul; 92(2):369-76. PubMed ID: 11466692
[TBL] [Abstract][Full Text] [Related]
20. A melanoma immune response signature including Human Leukocyte Antigen-E.
Tremante E; Ginebri A; Lo Monaco E; Benassi B; Frascione P; Grammatico P; Cappellacci S; Catricalà C; Arcelli D; Natali PG; Di Filippo F; Mottolese M; Visca P; Benevolo M; Giacomini P
Pigment Cell Melanoma Res; 2014 Jan; 27(1):103-12. PubMed ID: 24011128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
